SCHEMBL274916

SCHEMBL274916

CCCOC(=O)C(=O)CBr

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
TRPA1 O75762 2/20 0.41
HCAR2 Q8TDS4 1/20 0.39
FAAH O00519 2/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TSHR P16473 3/20 0.36
LMNA P02545 1/20 0.36
CYP2C19 P33261 1/20 0.35
ESR1 P03372 1/20 0.35
CHRM1 P11229 1/20 0.35
SLC6A2 P23975 1/20 0.35
KDR P35968 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
THRB P10828 1/20 0.33
ATM Q13315 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11445339 0.86 ALDH1A1 (0.52) ALDH1A1HCAR2FAAHSMN1; SMN2TSHR
SCHEMBL5174796 0.85 TSHR (0.55) ALDH1A1HCAR2FAAHTSHRLMNA
SCHEMBL11433560 0.83 TSHR (0.58) ALDH1A1HCAR2FAAHTSHRLMNA
SCHEMBL19813741 0.83 TSHR (0.58) ALDH1A1HCAR2FAAHTSHRLMNA
SCHEMBL19813747 0.83 TSHR (0.58) ALDH1A1HCAR2FAAHTSHRLMNA
SCHEMBL7108037 0.81 HCAR2 (0.37) ALDH1A1TRPA1HCAR2FAAHGAA
SCHEMBL7108033 0.81 HCAR2 (0.37) ALDH1A1TRPA1HCAR2FAAHGAA
SCHEMBL16044867 0.80 HCAR2 (0.41) ALDH1A1HCAR2FAAHGAASMN1; SMN2
SCHEMBL3020479 0.80 HCAR2 (0.41) ALDH1A1HCAR2FAAHGAASMN1; SMN2
SCHEMBL16045838 0.80 GAA (0.43) ALDH1A1HCAR2GAASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022384-A1 ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF OSPEDALE SAN RAFFAELE S.R.L. (IT) 2026-01-22 US claimed
WO-2025042868-A1 COMBINATIONS OF HETEROAROTINOIDS AND GLYCOLYTIC INHIBITORS FOR USE AS CANCER TREATMENTS THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) 2025-02-27 WO claimed
US-20250017950-A1 COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS UCL BUSINESS LTD (GB) 2025-01-16 US claimed
EP-4433077-A1 COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS UCL Business Ltd (GB) 2024-09-25 EP claimed
CN-221528993-U Optical system 浙江舜宇光学有限公司 2024-08-13 CN claimed
CN-117310997-A Optical system 浙江舜宇光学有限公司 2023-12-29 CN claimed
US-20230181621-A1 ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF OSPEDALE SAN RAFFAELE S.R.L. (IT) 2023-06-15 US claimed
WO-2023089313-A1 COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS UCL BUSINESS LTD (GB) 2023-05-25 WO claimed
CN-115933203-A Optical system and VR equipment including the same 浙江舜宇光学有限公司 2023-04-07 CN claimed
CN-115149932-A Mixed modulation method for restraining EMI (electro-magnetic interference) applied to motor driving chip 嘉兴禾润电子科技有限公司 2022-10-04 CN claimed
CN-114212063-A Method and device for determining electronic parking clamping force 中国第一汽车股份有限公司 2022-03-22 CN claimed
WO-2022055285-A1 PHARMACEUTICAL COMPOSITION FOR KILLING CANCER PROGENITOR CELLS 연세대학교 산학협력단 2022-03-17 WO claimed
CN-115712191-B Large aperture lens 舜宇光学(中山)有限公司 2026-05-19 CN disclosed
US-20260022384-A1 ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF OSPEDALE SAN RAFFAELE S.R.L. (IT) 2026-01-22 US disclosed
CN-120150892-A Phase passive compensation method and device for wavelength division multiplexing long-distance optical transmission link 中国电子科技集团公司第三十八研究所 2025-06-13 CN disclosed
CN-120060152-A Cell model for high-throughput screening of 2-DG anti-renal cancer drugs and construction method and application thereof 宿州学院 2025-05-30 CN disclosed
US-20050054634-A1 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents AKARNA THERAPEUTICS, LTD. (GB) 2005-03-10 US disclosed
US-20040023947-A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents X-CEPTOR THERAPEUTICS INC. 2004-02-05 US disclosed
WO-2003099821-A1 AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X-CEPTOR THERAPEUTICS, INC. (US) 2003-12-04 WO disclosed
US-4560690-A ANTISECRETORY AGENTS, HISTAMINE H2-ANTAGONISTS PFIZER INC. (US) 1985-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023947-A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents HTR5A, MTNR1A, PTGDR ALDH1A1 1722/4885TRPA1 754/4885HCAR2 64/4885
US-20230181621-A1 ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF ASNS, GLS, GLS2 ALDH1A1 2207/4885TRPA1 4764/4885HCAR2 1976/4885
US-20250017950-A1 COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS POLRMT, TK2, GOT2 ALDH1A1 1791/4885TRPA1 4851/4885HCAR2 2884/4885
US-20050054634-A1 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents GPR119, IRS1, INSR ALDH1A1 3963/4885TRPA1 459/4885HCAR2 38/4885
US-20260022384-A1 ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF ASNS, AARS1, NARS1 ALDH1A1 3160/4885TRPA1 3648/4885HCAR2 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.